New drugs for ALS: How do we get there?

Experimental Neurology

Volumn 233, Issue 1, 2012, Pages 112-117

  Glass, Jonathan D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; CEFTRIAXONE; CYSTATIN C; GLUTAMATE TRANSPORTER; NEUROFILAMENT H PROTEIN; NEUROFILAMENT PROTEIN; RILUZOLE; TAR DNA BINDING PROTEIN; TRICHOSTATIN A; UBIQUILIN 2; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; CELL INCLUSION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ELECTRICAL IMPEDANCE MYOGRAPHY; ELECTROMYOGRAPHY; HUMAN; MOLECULAR GENETICS; MOTOR UNIT NUMBER ESTIMATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NOTE; PATIENT CODING; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RATING SCALE; REVISED AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; THERAPY EFFECT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HYDROXAMIC ACIDS; MALE; MOTOR NEURONS; NEUROMUSCULAR JUNCTION; SPINAL CORD;

EID: 84856223048     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.10.007     Document Type: Note

References (78)

1. Abbott A. Neurologists strike gold in drug screen effort. Nature 2002, 417:109.
2. Abramson V., Arteaga C.L. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin. Cancer Res. 2011, 17:952-958.
3. Anderson K.J., Scheff S.W., Miller K.M., Roberts K.N., Gilmer L.K., Yang C., Shaw G. The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J. Neurotrauma 2008, 25:1079-1085.
4. Andreassi C., Angelozzi C., Tiziano F.D., Vitali T., De Vincenzi E., Boninsegna A., Villanova M., Bertini E., Pini A., Neri G., Brahe C. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 2004, 12:59-65.
5. BDNF A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF study group (phase III). Neurology 1999, 52:1427-1433.
6. Bowser R., Cudkowicz M., Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert. Rev. Mol. Diagn. 2006, 6:387-398.
7. Boylan K., Yang C., Crook J., Overstreet K., Heckman M., Wang Y., Borchelt D., Shaw G. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J. Neurochem. 2009, 111:1182-1191.
8. Brichta L., Holker I., Haug K., Klockgether T., Wirth B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol. 2006, 59:970-975.
9. Chio A., Calvo A., Moglia C., Mazzini L., Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J. Neurol. Neurosurg. Psychiatry 2011, 82:740-746.
10. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009, 32:591-601.
11. Coleman M.P., Perry V.H. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 2002, 25:532-537.
12. Conforti L., Adalbert R., Coleman M.P. Neuronal death: where does the end begin?. Trends Neurosci. 2007, 30:159-166.
13. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Zhang H., Andreasson K.I., Rothstein J.D., Drachman D.B. Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 2006, 60:22-31.
14. Cudkowicz M.E., Andres P.L., Macdonald S.A., Bedlack R.S., Choudry R., Brown R.H., Zhang H., Schoenfeld D.A., Shefner J., Matson S., Matson W.R., Ferrante R.J. Phase 2 study of sodium phenylbutyrate in ALS. Amyotrophic Lateral Sclerosis: Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2009, 10:99-106.
15. Cudkowicz M.E., Katz J., Moore D.H., O'Neill G., Glass J.D., Mitsumoto H., Appel S., Ravina B., Kieburtz K., Shoulson I., Kaufmann P., Khan J., Simpson E., Shefner J., Levin B., Cwik V., Schoenfeld D., Aggarwal S., McDermott M.P., Miller R.G. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2009.
16. Dejesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G.Y., Karydas A., Seeley W.W., Josephs K.A., Coppola G., Geschwind D.H., Wszolek Z.K., Feldman H., Knopman D.S., Petersen R.C., Miller B.L., Dickson D.W., Boylan K.B., Graff-Radford N.R., Rademakers R. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron 2011, 72:245-256.
17. Del Signore S.J., Amante D.J., Kim J., Stack E.C., Goodrich S., Cormier K., Smith K., Cudkowicz M.E., Ferrante R.J. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler. 2009, 10:85-94.
18. Deng H.X., Chen W., Hong S.T., Boycott K.M., Gorrie G.H., Siddique N., Yang Y., Fecto F., Shi Y., Zhai H., Jiang H., Hirano M., Rampersaud E., Jansen G.H., Donkervoort S., Bigio E.H., Brooks B.R., Ajroud K., Sufit R.L., Haines J.L., Mugnaini E., Pericak-Vance M.A., Siddique T. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477:211-215.
19. Dickson D.W., Josephs K.A., Amador-Ortiz C. TDP-43 in differential diagnosis of motor neuron disorders. Acta Neuropathol. 2007, 114:71-79.
20. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 2002, 52:771-778.
21. d'Ydewalle C., Krishnan J., Chiheb D.M., Van Damme P., Irobi J., Kozikowski A.P., Vanden Berghe P., Timmerman V., Robberecht W., Van Den Bosch L. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat. Med. 2011, 17:968-974.
22. Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 2004, 185:232-240.
23. Gardian G., Browne S.E., Choi D.K., Klivenyi P., Gregorio J., Kubilus J.K., Ryu H., Langley B., Ratan R.R., Ferrante R.J., Beal M.F. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280:556-563.
24. Geser F., O'Dwyer L., Hardiman O., Bede P., Bokde A.L., Prvulovic D., Trojanowski J.Q., Hampel H. On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog. Neurobiol. 2011.
25. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., Neville H.E., Boylan K., Mozaffar T., Belsh J.M., Ravits J., Bedlack R.S., Graves M.C., McCluskey L.F., Barohn R.J., Tandan R. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6:1045-1053.
26. Gordon P.H., Cheung Y.K., Levin B., Andrews H., Doorish C., Macarthur R.B., Montes J., Bednarz K., Florence J., Rowin J., Boylan K., Mozaffar T., Tandan R., Mitsumoto H., Kelvin E.A., Chapin J., Bedlack R., Rivner M., McCluskey L.F., Pestronk A., Graves M., Sorenson E.J., Barohn R.J., Belsh J.M., Lou J.S., Levine T., Saperstein D., Miller R.G., Scelsa S.N. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotrophic Lateral Sclerosis: Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2008, 9:212-222.
27. Gould T.W., Buss R.R., Vinsant S., Prevette D., Sun W., Knudson C.M., Milligan C.E., Oppenheim R.W. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J. Neurosci. 2006, 26:8774-8786.
28. Groeneveld G.J., Veldink J.H., van der Tweel I., Kalmijn S., Beijer C., de Visser M., Wokke J.H., Franssen H., van den Berg L.H. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. 2003, 53:437-445.
29. Gurney M.E., Fleck T.J., Himes C.S., Hall E.D. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998, 50:62-66.
30. Hogarth P., Lovrecic L., Krainc D. Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Mov. Disord. 2007, 22:1962-1964.
31. Howland D.S., Liu J., She Y., Goad B., Maragakis N., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., DeGennaro L.J., Cleveland D.W., Rothstein J.D. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1604-1609.
32. Igaz L.M., Kwong L.K., Lee E.B., Chen-Plotkin A., Swanson E., Unger T., Malunda J., Xu Y., Winton M.J., Trojanowski J.Q., Lee V.M. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Investig. 2011, 121:726-738.
33. Ikeda K., Iwasaki Y., Kinoshita M. Oral administration of creatine monohydrate retards progression of motor neuron disease in the wobbler mouse. Amyotroph. Lateral Scler. 2000, 1:207-212.
34. Jack C.R., Vemuri P., Wiste H.J., Weigand S.D., Aisen P.S., Trojanowski J.Q., Shaw L.M., Bernstein M.A., Petersen R.C., Weiner M.W., Knopman D.S. Evidence for ordering of Alzheimer disease biomarkers. Arch. Neurol. 2011.
35. Janne P.A., Johnson B.E. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 2006, 12:4416s-4420s.
36. Jeong M.R., Hashimoto R., Senatorov V.V., Fujimaki K., Ren M., Lee M.S., Chuang D.M. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett. 2003, 542:74-78.
37. Kasai T., Tokuda T., Ishigami N., Sasayama H., Foulds P., Mitchell D.J., Mann D.M., Allsop D., Nakagawa M. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009, 117:55-62.
38. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003, 301:839-842.
39. Kaufmann P., Levy G., Thompson J.L., Delbene M.L., Battista V., Gordon P.H., Rowland L.P., Levin B., Mitsumoto H. The ALSFRSr predicts survival time in an ALS clinic population. Neurology 2005, 64:38-43.
40. Kelley R.K., Venook A.P. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?. Clin. Colorectal Cancer 2011, 10:73-80.
41. Kishino A., Ishige Y., Tatsuno T., Nakayama C., Noguchi H. BDNF prevents and reverses adult rat motor neuron degeneration and induces axonal outgrowth. Exp. Neurol. 1997, 144:273-286.
42. Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., Mueller G., Wermer M., Kaddurah-Daouk R., Beal M.F. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 1999, 5:347-350.
43. Lam B., Hollingdrake E., Kennedy J.L., Black S.E., Masellis M. Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum. Genomics 2009, 4:91-106.
44. Leigh P.N., Anderton B.H., Dodson A., Gallo J.M., Swash M., Power D.M. Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci. Lett. 1988, 93:197-203.
45. Levy G., Kaufmann P., Buchsbaum R., Montes J., Barsdorf A., Arbing R., Battista V., Zhou X., Mitsumoto H., Levin B., Thompson J.L. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006, 66:660-663.
46. Lou J.S., Moore D., Gordon P.H., Miller R. Correlates of quality of life in ALS: lessons from the minocycline study. Amyotrophic Lateral Sclerosis: Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2010, 11:116-121.
47. Mackenzie I.R., Bigio E.H., Ince P.G., Geser F., Neumann M., Cairns N.J., Kwong L.K., Forman M.S., Ravits J., Stewart H., Eisen A., McClusky L., Kretzschmar H.A., Monoranu C.M., Highley J.R., Kirby J., Siddique T., Shaw P.J., Lee V.M., Trojanowski J.Q. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 2007, 61:427-434.
48. Natasha G., Brandom K.G., Young E.C., Young P.J. Valproate and spinal muscular atrophy (review). Mol. Med. Rep. 2008, 1:161-165.
49. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
50. Otto, M., Bowser, R., Turner, M., Berr, Y.J., Brettschneider, J., Connor, J., Costa, J., Cudkowicz, M., Glass, J., Jahn, O., Lehnert, S., Malaspina, A., Parnetti, L., Petzold, A., Shaw, P., Sherman, A., Steinacker, P., Süßmuth, S., Teunissen, C., Tumani, H., Wuolikainen, A., Ludolph, A., 2012. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph. Lateral Scler. 13, 1-10.
51. Reijn T.S., Abdo W.F., Schelhaas H.J., Verbeek M.M. CSF neurofilament protein analysis in the differential diagnosis of ALS. J. Neurol. 2009, 256:615-619.
52. Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., Kalimo H., Paetau A., Abramzon Y., Remes A.M., Kaganovich A., Scholz S.W., Duckworth J., Ding J., Harmer D.W., Hernandez D.G., Johnson J.O., Mok K., Ryten M., Trabzuni D., Guerreiro R.J., Orrell R.W., Neal J., Murray A., Pearson J., Jansen I.E., Sondervan D., Seelaar H., Blake D., Young K., Halliwell N., Callister J.B., Toulson G., Richardson A., Gerhard A., Snowden J., Mann D., Neary D., Nalls M.A., Peuralinna T., Jansson L., Isoviita V.M., Kaivorinne A.L., Holtta-Vuori M., Ikonen E., Sulkava R., Benatar M., Wuu J., Chio A., Restagno G., Borghero G., Sabatelli M., Heckerman D., Rogaeva E., Zinman L., Rothstein J.D., Sendtner M., Drepper C., Eichler E.E., Alkan C., Abdullaev Z., Pack S.D., Dutra A., Pak E., Hardy J., Singleton A., Williams N.M., Heutink P., Pickering-Brown S., Morris H.R., Tienari P.J., Traynor B.J. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron 2011, 72:257-268.
53. Risacher S.L., Shen L., West J.D., Kim S., McDonald B.C., Beckett L.A., Harvey D.J., Jack C.R., Weiner M.W., Saykin A.J. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol. Aging 2010, 31:1401-1418.
54. Rothstein J.D., Tsai G., Kuncl R.W., Clawson L., Cornblath D.R., Drachman D.B., Pestronk A., Stauch B.L., Coyle J.T. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 1990, 28:18-25.
55. Rothstein J.D., Martin L., Kuncl R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 1992, 326:1464-1468.
56. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., Fisher P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
57. Rutkove S. Electrical impedance myography as a biomarker for ALS. Lancet Neurol. 2009, 8:226. author reply 227.
58. Ryu H., Lee J., Olofsson B.A., Mwidau A., Dedeoglu A., Escudero M., Flemington E., Azizkhan-Clifford J., Ferrante R.J., Ratan R.R. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4281-4286.
59. Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown R.H., Ferrante R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005, 93:1087-1098.
60. Samtani M.N., Farnum M., Lobanov V., Yang E., Raghavan N., Dibernardo A., Narayan V., Initiative A.D. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J. Clin. Pharmacol. 2011.
61. Sardana D., Zhu C., Zhang M., Gudivada R.C., Yang L., Jegga A.G. Drug repositioning for orphan diseases. Brief. Bioinform. 2011, 12:346-356.
62. Sargent D.J., Marsoni S., Monges G., Thibodeau S.N., Labianca R., Hamilton S.R., French A.J., Kabat B., Foster N.R., Torri V., Ribic C., Grothey A., Moore M., Zaniboni A., Seitz J.F., Sinicrope F., Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 2010, 28:3219-3226.
63. Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton M., Urbinelli L., Qureshi M., Zhang H., Pestronk A., Caress J., Donofrio P., Sorenson E., Bradley W., Lomen-Hoerth C., Pioro E., Rezania K., Ross M., Pascuzzi R., Heiman-Patterson T., Tandan R., Mitsumoto H., Rothstein J., Smith-Palmer T., MacDonald D., Burke D. A clinical trial of creatine in ALS. Neurology 2004, 63:1656-1661.
64. Shefner J.M., Watson M.L., Simionescu L., Caress J.B., Burns T.M., Maragakis N.J., Benatar M., David W.S., Sharma K.R., Rutkove S.B. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology 2011, 77:235-241.
65. Sorenson E.J., Windbank A.J., Mandrekar J.N., Bamlet W.R., Appel S.H., Armon C., Barkhaus P.E., Bosch P., Boylan K., David W.S., Feldman E., Glass J., Gutmann L., Katz J., King W., Luciano C.A., McCluskey L.F., Nash S., Newman D.S., Pascuzzi R.M., Pioro E., Sams L.J., Scelsa S., Simpson E.P., Subramony S.H., Tiryaki E., Thornton C.A. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008, 71:1770-1775.
66. Stallings N.R., Puttaparthi K., Luther C.M., Burns D.K., Elliott J.L. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 2010, 40:404-414.
67. Sugai F., Yamamoto Y., Miyaguchi K., Zhou Z., Sumi H., Hamasaki T., Goto M., Sakoda S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 2004, 20:3179-3183.
68. Sui M., Zhang H., Fan W. The role of estrogen and estrogen receptors in chemoresistance. Curr. Med. Chem. 2011.
69. Suzuki M., McHugh J., Tork C., Shelley B., Klein S.M., Aebischer P., Svendsen C.N. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One 2007, 2:e689.
70. Suzuki M., McHugh J., Tork C., Shelley B., Hayes A., Bellantuono I., Aebischer P., Svendsen C.N. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther. 2008, 16:2002-2010.
71. Swarup V., Phaneuf D., Bareil C., Robertson J., Rouleau G.A., Kriz J., Julien J.P. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 2011, 134:2610-2626.
72. Tafe L.J., Tsongalis G.J. The Human Epidermal Growth Factor Receptor 2 (HER2). Clinical Chemistry and Laboratory Medicine: CCLM/FESCC 2011.
73. Uo T., Veenstra T.D., Morrison R.S. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. J. Neurosci. 2009, 29:2824-2832.
74. Wegorzewska I., Bell S., Cairns N.J., Miller T.M., Baloh R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18809-18814.
75. Weihl C.C., Connolly A.M., Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006, 67:500-501.
76. Wilson M.E., Boumaza I., Lacomis D., Bowser R. Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS One 2010, 5:e15133.
77. Yoo Y.E., Ko C.P. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2011, 231:147-159.
78. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu du C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417:74-78.